Sanofi holds the cleaner structural position, with stability as the main driver and growth adding further support. Zimmer Biomet still has the edge on valuation, which keeps the comparison from looking entirely one-sided. Both sides have seen trend damage — neither carries a clear market edge right now. With both trends damaged, the structural comparison carries most of the weight here.
The comparison is based on similar long-term financial trajectories, not sector labels.
The lead is spread across stability and growth, rather than sitting in one isolated gap. Sanofi leads by 10 points on the overall comparison score.
This comparison is anchored in long-term financial trajectory similarity within the selected peer universe.
The pair shares a valid long-term profile match, but the trajectories are not especially close.
The clearest structural overlap shows up in revenue stability and margin consistency.
Scores reflect position relative to comparable companies with similar long-term financial trajectories.
The largest gaps do not all point in the same direction.
Left means cheaper relative valuation. Higher means stronger structure.
The setup stays mixed because structure and the price setup do not align cleanly in one direction.
Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.
The stability gap is wide, with the stronger side looking materially steadier through time.
A meaningful counterforce remains in valuation, which keeps the comparison from looking completely one-sided.
Stability is the clearest driver of the lead, with growth adding further support — though valuation still provides a real counterweight.
Break down the SAN.PA vs ZBH comparison across all dimensions with the full interactive tool.
Explore how SAN.PA and ZBH each compare against other companies in their peer groups.
Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.
AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.
Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.
Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.